Lupin Secures US FDA Approval for Amifampridine Tablets with 180-Day Shared Exclusivity
Lupin Ltd 路 Press Release 路 02 Nov 2026, 11:34 pm
Lupin Secures US FDA Approval for Amifampridine Tablets with 180-Day Shared Exclusivity Lupin has received US FDA approval for its Abbreviated New Drug Application for Amifampridine Tablets, 10 mg, bioequivalent to Catalyst Pharmaceuticals' reference listed drug, Firdapse Tablets, 10 mg. As one of the first ANDA applicants, Lupin is eligible for 180 days of shared generic exclusivity in the US market.
Original exchange filing (PDF)
More announcements from Lupin Ltd
- Lupin Announces European Launch of Biosimilar Ranibizumab. 路 12 Nov 2026
- Transcript of Q2 FY2027 Earnings Conference Call. 路 07 Nov 2026
- Link of Audio recording of the Earnings Call-Q2 FY27. 路 05 Nov 2026
- Investor Presentation- Q2 FY2027 路 04 Nov 2026
- Lupin Q2 FY2027 Results 路 04 Nov 2026
- Appointment of Mr. Akhil Gupta as an Additional Director (Non-Executive, Independent) effective November 03, 2026 and as an Independent Director for a term of five consecutive years with .... 路 04 Nov 2026
- Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026. 路 04 Nov 2026
- Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026. 路 04 Nov 2026
